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Clinical trials objectives
Although it may seem self-evident, it is important when
establishing a clinical trial that there is an important question
to be answered. Once such a question has been posed and
an appropriate design established to answer that question, all
efforts should be made to enrol as many patients into the trial
as expeditiously as possible. The design of the trial should
support that aim.
Eligibility criteria
Eligibility criteria should not be too elaborate or complex. For
example, in an adjuvant breast cancer trial, specific details of
the exact handling of tumour margins, exact doses of
radiation therapy or number of nodes dissected may not be
particularly important in comparison with entering a wide
variety of patients from the adjuvant setting. Broader entry
criteria will make trial results more generalizable and will
result in more rapid trial accrual. It is important, however, that
eligibility criteria ensure that the patients entered will be
receiving therapy that is safe for them, and that the stated
end-point(s) of the study can be obtained in all patients.
Data collection
Ideally, patients should be enrolled into large simple trials
with simple outcomes such as recurrence of cancer and
death. Such trials could be conducted relatively economically.
In turn, however, we must balance simplicity against the need
to collect important data. For example, if we compare two
treatment regimens in a trial of adjuvant therapy for breast
cancer, then we would want to collect toxicity data carefully.
We may also be required by agencies such as the US Food
and Drug Administration and the European Medicines
Agency to collect certain data in order to meet registration
requirements. In terms of outcome, one may not want to
collect only the first site of recurrence, but patterns of
recurrence; for example, does the patient initially or later
develop a brain mestastasis or a bone metastasis. Further-
more, once a trial is completed, useful information can be
obtained by studying concurrent medications if they are
recorded. For example, it is believed that providing local
vaginal oestrogen therapy may obviate the systemic adjuvant
effect of the aromatase inhibitors, because there may be sys-
temic absorption of such oestrogen. However, in a large trial
of aromatase inhibitor versus placebo (MA.17) [1], although
vaginal oestrogens were allowed, there was no systematic
recording of their use and so a study of this interesting
question in the setting of this randomized clinical trial may be
difficult. Overall, one must strike a balance between
collecting data that will never be used and not collecting data
that one may later wish to have had.
Clinical trial hurdles
To create a clinical trial, it is still important to generate the
question, write a protocol and seek funding for the trial.
Regulatory approval will be involved. Most institutions have
protocol review committees, which judge the science of the
study and its impact on clinical practice in the institution.
Separate committees (research ethics boards [REBs]) exist
to judge ethical suitability and to review the process for
informed consent. Contracts between the hospital and the
sponsor of the trial are complex and often take considerable
time to negotiate. Standard operating procedures for clinical
trials must be adhered to and systematic reporting of adverse
events, and particularly serious adverse events (SAEs), is
required. These are just some of the many critical but time
consuming issues that are involved in launching and
conducting a study. As the bureaucracy and paperwork
required increases and costs escalate, more trials may be run
by industry and fewer by academic investigators.
The best trials are designed by investigators with burning
questions to answer! However, a shortage of oncologists and
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clinical  service demands are a threat to the development of
young clinical investigators. It will be important over future years
to protect the time of these young investigators and to help
them to pose important questions, put together well designed
protocols and learn to seek the funding to carry them out.
There are also important issues surrounding the issue of who
should hold datasets. There are felt to be conflicts of interest
when industry holds data and manages analyses, but they
may be best equipped to do so because they have greater
economical and data management resources, and employ
many statistical experts. Running trials at academic insti-
tutions has become increasingly difficult, particularly because
many peer-reviewed funding agencies often systematically
under-fund clinical trials in the peer review grant process.
Within institutions, financial cutbacks have led to a tendency
by hospitals to bill for every incremental procedure, test or
activity that is required as part of a clinical trial. Some
institutions would like to charge for every activity for a patient
as long as they are in a study, even though the patient might
undergo many of those same procedures in routine care.
Because breast cancer has such a long natural history,
ongoing follow-up is important. Often there is not sufficient
funding to carry out this activity, however. There have been
proposals to match patients on long-term follow up in the
adjuvant setting to cancer registries in order to record
accurately adverse events, recurrence, death and cause of
death. For example, many of the data on long-term side
effects of tamoxifen were first clearly described in the
Scandinavian countries, in which cancer registries are very
accurate, by matching up patients in large randomized clinical
trials with those included in registries (for instance,
tamoxifen’s association with endometrial cancer [2] and the
reduction in cardiac disease shown with tamoxifen [3]).
Regulatory approval has become increasingly difficult in
countries such as Canada. Clinical trials approval is now
required even for drugs that have been commercially available
for a long time but are being tested at a slightly different
dosage or combination. This has added to the administrative
burden of trial conduct. Protocol submissions and reviews
have become more complex. Every trial, as it should, requires
yearly approval and re-REB consideration. And then there are
amendments! Recent regulations suggest that when sub-
stantial amendments to a trial are ongoing and have not been
passed through the local REB, accrual to the trial must be
suspended. This results in frequent interruptions to trial
accrual. Auditing, although clearly necessary to ensure that
source documentation for study-collected information is
available and accurate, consumes the time of both the
auditors and the trials personnel in the centres.
Studies are often designed with a lot of scientific thought,
and then re-reviewed by several layers of review committees,
including ethics boards, whose members may want to revise
the science. Consent forms are becoming increasingly
complex and, unfortunately, are directed more at legal protec-
tion of institutions, physicians and other health professionals
than at explaining the study to the patient. Many consent
forms in North America are now 10 to 12 pages long. It is
unlikely that patients actually absorb and understand all of
this material. A simpler approach would probably be more
effective. Contracts have also become complex, in part
because of the many legal issues surrounding confidentiality
and indemnification.
The trial investigators Good Clinical Practice handbook,
while setting a clear standard for the conduct of trials, can be
interpreted in many different ways [4]. These different inter-
pretations often present difficulties.
Solutions
Trialists are moving forward to deal with many of these issues
in a more efficient way. Making entry criteria to studies very
broad allows greater generalizability. In addition, trialists have
developed mechanisms for advertising studies and for
screening broad populations for their availability to enter.
Websites such as Patient Data Query [5] list available
studies, whereas others such as the Ontario Institute for
Cancer Research website [6] show not only what trials may
be available for patients with a particular stage or phase of
breast cancer or other diseases, but also what institutions are
conducting these studies.
The current systems for reporting SAEs result in multiple
reports of the same events to the same investigators and lead
to a large burden of paperwork that often obscures the few
important SAEs that may be reported. Organizations such as
the National Cancer Institute of Canada Clinical Trials Group
now screen and streamline such SAEs before sending them
out to individual centres so that fewer, more relevant SAEs
can be considered in more detail.
The use of centralized REBs may also reduce repetitive work
within each centre. For example, the Ontario Cancer
Research Ethics Board has been developed to streamline
ethics approval and appears to be filling this role [7].
Conclusion
A plethora of regulatory and ethics requirements around
clinical trials has made them slower to initiate and more
difficult and expensive to conduct. Although many of the
issues that this bureaucracy is designed to regulate are
important ones, it is to be hoped that in the future clinical
trials can be streamlined so that they may be started faster,
conducted more cheaply and efficiently, and enter more
patients more quickly and with more generalizable results.
This would make the conduct of clinical trials more appealing
to investigators and patients, and their results more quickly
relevant and useful. It is important for investigators, regulatoryPage 3 of 3
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agencies, ethics bodies and funding agencies to keep these
issues in mind as they move forward in designing the clinical
trials of the future.
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